Hi Chris, I just looked. Actually as far as I'm concerned at this point all I care about on these stocks is the cash flow statement, so kind of trying to piece that together myself here, but missing pieces to the puzzle.
Cash declined about net 15 cents per share, but was helped by both acc rec and inv declines. Not sure how much cash that little acquisition took. Current Q is supposed to be worse from sales, but can be at least partially offset because no acquisition and lower costs. Maybe cash burn will be about the same.
But it looks like INTT can only take about 5-6 "Q"'s of this environment before it goes bust. And 2009 is supposed to suck,
so it could be close.
That's what makes a market: stock priced at 60 pennies, might go bust, but if they survive the down cycle, could be a $4+ stock again.
INTT has plenty of penny stock company in the sector:
ASYT, ACLS, EGLS, FSII, LTXC, NVMI, PLAB.
Hey, I like the odds better than the average cash burning dilution machine small cap biotech. And the balance sheets are sure cleaner than a bank! |
